Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
$37.79M
Mr. Matthias Alder LIC. IUR., LL.M.
25.00
Bethesda, MD
Mar 18, 2021
-1.13
$-1.31
2.60
2.84
-33,332.57%
-1.33
0.02
2.44
589.13
2.84
-112.52%
-214.20%
Similar stocks (12)
Celcuity Inc.
CELC
Eliem Therapeutics, Inc.
ELYM
Inhibrx, Inc.
INBX
aTyr Pharma, Inc.
LIFE
MediciNova, Inc.
MNOV
Champions Oncology, Inc.
CSBR
Anebulo Pharmaceuticals, Inc.
ANEB
Lantern Pharma Inc.
LTRN
Cue Biopharma, Inc.
CUE
BioVie Inc.
BIVI
IN8bio, Inc.
INAB
TFF Pharmaceuticals, Inc.
TFFP
ETF Exposure (3)
iShares Micro-Cap ETF
IWC
0.00488%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (12)
Celcuity Inc.
CELC
Eliem Therapeutics, Inc.
ELYM
Inhibrx, Inc.
INBX
aTyr Pharma, Inc.
LIFE
MediciNova, Inc.
MNOV
Champions Oncology, Inc.
CSBR
Anebulo Pharmaceuticals, Inc.
ANEB
Lantern Pharma Inc.
LTRN
Cue Biopharma, Inc.
CUE
BioVie Inc.
BIVI
IN8bio, Inc.
INAB
TFF Pharmaceuticals, Inc.
TFFP
ETF Exposure (3)
iShares Micro-Cap ETF
IWC
0.00488%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%